Finding 1056003 (2022-014)

Material Weakness Repeat Finding
Requirement
L
Questioned Costs
-
Year
2022
Accepted
2024-07-29

AI Summary

  • Core Issue: The Organization failed to prepare a complete Schedule of Expenditures of Federal Awards (SEFA) that aligns with the trial balance.
  • Impacted Requirements: SEFA preparation is mandatory for organizations spending over $750,000 in federal funds, as per federal regulations.
  • Recommended Follow-Up: Management should implement a tracking system for federal grant funds and ensure reconciliation with the general ledger to avoid future discrepancies.

Finding Text

Formerly 2021-005: Reporting Federal Program: Assistance Listing No.: 14.267 Continuum of Care Program (“CoC”) & 93.558 Temporary Assistance for Needy Families (TANF) Condition: The Organization did not prepare a complete Schedule of Expenditures of Federal Awards that was able to be verified and tie out to trial balance. Criteria: The Schedule of Expenditures of Federal Awards ("SEFA") is required under federal regulations to be prepared by the Auditee by funding organizations when spending $750,000 or more in federal funds. Questioned Costs: There are no questioned costs. Cause: The Organization did not have sufficient controls over the tracking of federal and state expenditures and reconciled to the general ledger. Effect: The Organization could have expenditures reported on the SEFA that should not be or ones that should have been reported but were not reported on the SEFA. Recommendation: In order to prevent future occurrences of this deficiency, we recommend that management develop a method to track federal grant funds and the use of those funds and reconcile both to the general ledger. Perspective: This is a systemic issue in that controls over the requirement have not been developed to ensure that reported information is accurate. Repeat: This is a repeat finding. Responsible Official’s View: The Organization agrees with the finding. See attached corrective action plan.

Categories

Reporting

Other Findings in this Audit

  • 479551 2022-013
    Material Weakness
  • 479552 2022-013
    Material Weakness
  • 479553 2022-014
    Material Weakness Repeat
  • 479554 2022-014
    Material Weakness Repeat
  • 479555 2022-014
    Material Weakness Repeat
  • 479556 2022-014
    Material Weakness Repeat
  • 479557 2022-014
    Material Weakness Repeat
  • 479558 2022-014
    Material Weakness Repeat
  • 479559 2022-014
    Material Weakness Repeat
  • 479560 2022-014
    Material Weakness Repeat
  • 479561 2022-014
    Material Weakness Repeat
  • 479562 2022-015
    Material Weakness Repeat
  • 479563 2022-015
    Material Weakness Repeat
  • 479564 2022-015
    Material Weakness Repeat
  • 479565 2022-015
    Material Weakness Repeat
  • 479566 2022-016
    Material Weakness Repeat
  • 479567 2022-016
    Material Weakness Repeat
  • 479568 2022-016
    Material Weakness Repeat
  • 479569 2022-016
    Material Weakness Repeat
  • 479570 2022-017
    Material Weakness Repeat
  • 479571 2022-017
    Material Weakness Repeat
  • 479572 2022-017
    Material Weakness Repeat
  • 479573 2022-017
    Material Weakness Repeat
  • 479574 2022-018
    Material Weakness Repeat
  • 479575 2022-018
    Material Weakness Repeat
  • 479576 2022-018
    Material Weakness Repeat
  • 479577 2022-018
    Material Weakness Repeat
  • 479578 2022-018
    Material Weakness Repeat
  • 479579 2022-018
    Material Weakness Repeat
  • 1055993 2022-013
    Material Weakness
  • 1055994 2022-013
    Material Weakness
  • 1055995 2022-014
    Material Weakness Repeat
  • 1055996 2022-014
    Material Weakness Repeat
  • 1055997 2022-014
    Material Weakness Repeat
  • 1055998 2022-014
    Material Weakness Repeat
  • 1055999 2022-014
    Material Weakness Repeat
  • 1056000 2022-014
    Material Weakness Repeat
  • 1056001 2022-014
    Material Weakness Repeat
  • 1056002 2022-014
    Material Weakness Repeat
  • 1056004 2022-015
    Material Weakness Repeat
  • 1056005 2022-015
    Material Weakness Repeat
  • 1056006 2022-015
    Material Weakness Repeat
  • 1056007 2022-015
    Material Weakness Repeat
  • 1056008 2022-016
    Material Weakness Repeat
  • 1056009 2022-016
    Material Weakness Repeat
  • 1056010 2022-016
    Material Weakness Repeat
  • 1056011 2022-016
    Material Weakness Repeat
  • 1056012 2022-017
    Material Weakness Repeat
  • 1056013 2022-017
    Material Weakness Repeat
  • 1056014 2022-017
    Material Weakness Repeat
  • 1056015 2022-017
    Material Weakness Repeat
  • 1056016 2022-018
    Material Weakness Repeat
  • 1056017 2022-018
    Material Weakness Repeat
  • 1056018 2022-018
    Material Weakness Repeat
  • 1056019 2022-018
    Material Weakness Repeat
  • 1056020 2022-018
    Material Weakness Repeat
  • 1056021 2022-018
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
16.576 Crime Victim Compensation $273,735
93.788 Opioid Str $85,216
14.267 Continuum of Care Program $60,141
93.558 Temporary Assistance for Needy Families $47,833
16.588 Violence Against Women Formula Grants $36,160
94.006 Americorps $23,030
10.558 Child and Adult Care Food Program $20,513